Overview

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron
Tolterodine Tartrate